RECRUITINGINTERVENTIONAL

CCT for Comprehensive Risk Stratification Following STEMI

Cardiac Computed Tomography for Comprehensive Risk Stratification of Arrhythmic, Atherothrombotic and Heart Failure Events Following Reperfused ST-segment Elevation Myocardial Infarction

About This Trial

The CT-STEMI study aims to evaluate a comprehensive cardiac computed tomography (CCT) protocol for assessing the risk of heart failure (HF), life-threatening arrhythmias (LTA), and atherothrombotic events following ST-elevation myocardial infarction (STEMI). This multicenter, prospective study has three main objectives: 1. Comparing the diagnostic accuracy of the comprehensive CCT protocol with cardiac magnetic resonance (CMR), considered the non-invasive gold standard. 2. Determining the prognostic value of CCT in assessing myocardial tissue adverse features related to STEMI. 3. Evaluating the atherosclerotic burden in patients with post-acute STEMI. Two hundred patients will undergo both CCT and CMR in the post-acute phase, and their follow-up will focus on monitoring HF, LTA, and ischemic events. The CT-STEMI study represents the first attempt to assess the potential of CCT in providing a comprehensive risk assessment following STEMI in a large contemporary population. The findings of this study have the potential to revolutionize post-STEMI risk stratification practices.

Who May Be Eligible (Plain English)

Who May Qualify: - Signed willing to sign a consent form - STEMI diagnosis - Primary Percutaneous Coronary Intervention (PCI) \<24h from symptom onset - Hemodynamic stability without inotropic support within 4 days from the index event Who Should NOT Join This Trial: - Known chronic kidney disease with estimated Glomerular Filtration Rate (GFR) \< 30 mL/min/1.73mq - History of allergic reaction to CCT or CMR contrast media - Inability or unwilling to undergo CCT or CMR scanning - Pregnancy or breast-feeding - Severe atrial or ventricular arrhythmia burden - Severe valvular stenosis or regurgitation - Prior clinical congestive HF diagnosis (asymptomatic LV dysfunction can be included) Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Signed informed consent * STEMI diagnosis * Primary Percutaneous Coronary Intervention (PCI) \<24h from symptom onset * Hemodynamic stability without inotropic support within 4 days from the index event Exclusion Criteria: * Known chronic kidney disease with estimated Glomerular Filtration Rate (GFR) \< 30 mL/min/1.73mq * History of allergic reaction to CCT or CMR contrast media * Inability or unwilling to undergo CCT or CMR scanning * Pregnancy or breast-feeding * Severe atrial or ventricular arrhythmia burden * Severe valvular stenosis or regurgitation * Prior clinical congestive HF diagnosis (asymptomatic LV dysfunction can be included)

Treatments Being Tested

DIAGNOSTIC_TEST

Cardiac Computed Tomography

A comprehensive CCT protocol will be performed in the post-acute phase of STEMI. Specifically, the CCT protocol will include a pre-contrast scan and an angiographic scan ( also set up to assess ventricular volume and function) followed by late contrast enhancement scan.

DIAGNOSTIC_TEST

Cardiac Magnetic Resonance

A comprehensive CMR protocol will be performed in the post-acute phase of STEMI. Specifically, the CMR protocol is designed for morpho-functional analysis and tissue characterisation (including assessment of late gadolinium enhancement and mapping). CMR will be considered the gold standard.

Locations (3)

Azienda Ospedaliera Policlinico Universitario "G. Martino"

Messina, Italy

Istituto Auxologico Italiano - IRCCS - Ospedale San Luca

Milan, Italy

A.O.U. Città della Salute e della Scienza - Molinette Hospital

Turin, Italy